Studienregister

NeuroID

Psychoonkologische Wirksamkeit einer EEG Neurofeedback-Intervention bei Menschen mit malignem Melanom

Berufsordnung (BO) / Interventionell

Im Rahmen dieser Studie wurden psychoonkologische Patient*innen nach einer fünfwöchigen Warteliste randomisiert einer von zwei Interventionsbedingungen (Neurofeedback vs. Achtsamkeit) zugeteilt. Fragebogenerhebungen sowie EEG-Untersuchungen wurden vor der Warteliste, vor und nach der fünfwöchigen Intervention, sowie bei einem Follow-Up nach weiteren fünf Wochen durchgeführt.

Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC

EudraCT-Nummer: 2018-001974-76

R2810-ONC-1788

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma

EudraCT-Nummer: 2019-000566-38

ENCORAFENIB t BINIMETINIB

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria

Berufsordnung (BO) / Nicht-interventionell

Irina

Influence of timing of Radiotherapy on Immune respoNse to checkpoint blocker treatment in patients with metastasized melanomA

Arzneimittelgesetz (AMG) / Interventionell

Field_Cancerization

Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization. An open label, prospective, observational biomarker study of the DeCOG

Arzneimittelgesetz (AMG) / Phase 4, Interventionell, Multizentrisch

EudraCT-Nummer: 2021-006372-17

CA224-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresecable Melanoma

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-000575-39

NCT-Nummer: NCT05625399

C4221023 Portside

PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-THERAPY

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected High-Risk-Melanoma

Clinical Trial Regulation (CTR) / Interventionell

NCT-Nummer: NCT05608291

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

PH-L19IL2TNFNMSC-04/19

A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients

EudraCT-Nummer: 2020-003299-42

NCT-Nummer: NCT04362722

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

Berufsordnung (BO) / Nicht-interventionell

IOB-032/PN-E40

Phase II, multi-cohort trial of neoadjuvant and post-surgery IO102-IO103 and pembrolizumab in patients with selected resectable tumors

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

NCT-Nummer: NCT05280314

V940-001

Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

Arzneimittelgesetz (AMG) / Phase 3, Interventionell

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Target Engement of GSK1070806 SC injection in participants with Moderate to Severe Atopic Dermatitis

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

Das Studienregister der UME

- Klinik für Dermatologie -

Aktuelle Studien

NeuroID

Psychoonkologische Wirksamkeit einer EEG Neurofeedback-Intervention bei Menschen mit malignem Melanom

Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

R2810-ONC-1788

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

ENCORAFENIB t BINIMETINIB

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria

Irina

Influence of timing of Radiotherapy on Immune respoNse to checkpoint blocker treatment in patients with metastasized melanomA

Field_Cancerization

Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization. An open label, prospective, observational biomarker study of the DeCOG

CA224-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresecable Melanoma

C4221023 Portside

PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-THERAPY

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected High-Risk-Melanoma

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

PH-L19IL2TNFNMSC-04/19

A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

IOB-032/PN-E40

Phase II, multi-cohort trial of neoadjuvant and post-surgery IO102-IO103 and pembrolizumab in patients with selected resectable tumors

V940-001

Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Target Engement of GSK1070806 SC injection in participants with Moderate to Severe Atopic Dermatitis